Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             163 results found
no title author magazine year volume issue page(s) type
1 A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza Kung, Hsiang-Chi
 2010
 28 Supplement 3 p. 7337-7343
7 p.
 article
2 A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children Chokephaibulkit, Kulkanya
 2010
 28 Supplement 3 p. 3563-3566
4 p.
 article
3 A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia Carville, Kylie S.
 2010
 28 Supplement 3 p. 2532-2538
7 p.
 article
4 A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children Knuf, M.
 2010
 28 Supplement 3 p. 744-753
10 p.
 article
5 Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1–4-year-old Israeli children Passwell, Justen H.
 2010
 28 Supplement 3 p. 2231-2235
 article
6 Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP26 after nasopharyngeal colonization and acute otitis media in children Pichichero, Michael E.
 2010
 28 Supplement 3 p. 7184-7192
9 p.
 article
7 A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route Patel, Shital M.
 2010
 28 Supplement 3 p. 3025-3029
5 p.
 article
8 A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens Saraya, Abhinbhen
 2010
 28 Supplement 3 p. 4553-4557
5 p.
 article
9 A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months Esposito, Susanna
 2010
 28 Supplement 3 p. 6137-6144
8 p.
 article
10 A randomized controlled trial of analgesia during vaccination in adults Taddio, Anna
 2010
 28 Supplement 3 p. 5365-5369
5 p.
 article
11 A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits Gao, LuLu
 2010
 28 Supplement 3 p. 4445-4451
7 p.
 article
12 Are hard-to-reach populations being reached with immunization services? Findings from the 2005 Papua New Guinea national immunization coverage survey Toikilik, Steven
 2010
 28 Supplement 3 p. 4673-4679
7 p.
 article
13 A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx Kodama, Satoru
 2010
 28 Supplement 3 p. 2510-2516
7 p.
 article
14 A systematic review of measures for reducing injection pain during adult immunization Hogan, Mary-Ellen
 2010
 28 Supplement 3 p. 1514-1521
8 p.
 article
15 Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant Zhou, Qi
 2010
 28 Supplement 3 p. 1357-1362
6 p.
 article
16 A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting Goldstein, Gideon
 2010
 28 Supplement 3 p. 1008-1014
7 p.
 article
17 A 3-year follow-up of antibody response in HIV-infected children with immune recovery vaccinated with inactivated Japanese encephalitis vaccine Puthanakit, Thanyawee
 2010
 28 Supplement 3 p. 5900-5902
3 p.
 article
18 Bacterial ghosts (BGs)—Advanced antigen and drug delivery system Kudela, Pavol
 2010
 28 Supplement 3 p. 5760-5767
8 p.
 article
19 Carbohydrate moieties as vaccine candidates: Meeting summary Lucas, A.H.
 2010
 28 Supplement 3 p. 1121-1131
11 p.
 article
20 Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media Tsolakos, Nikos
 2010
 28 Supplement 3 p. 3211-3218
8 p.
 article
21 Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations Schlick, Petra
 2010
 28 Supplement 3 p. 5903-5909
7 p.
 article
22 Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines Steele, A.D.
 2010
 28 Supplement 3 p. 6542-6548
7 p.
 article
23 Co-expression of Flt-3 ligand gene ablates tumor immunity elicited by HER-2/neu DNA vaccine in transgenic mice Venanzi, F.M.
 2010
 28 Supplement 3 p. 3841-3847
7 p.
 article
24 Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-negative injection drug users Dhalla, Shayesta
 2010
 28 Supplement 3 p. 1663-1667
5 p.
 article
25 Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses Rodenburg, Gerwin D.
 2010
 28 Supplement 3 p. 1391-1396
6 p.
 article
26 Comparative evaluation of vaccine efficacy of recombinant Marek's disease virus vaccine lacking Meq oncogene in commercial chickens Lee, Lucy F.
 2010
 28 Supplement 3 p. 1294-1299
6 p.
 article
27 Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV) Shen, H.G.
 2010
 28 Supplement 3 p. 5960-5966
7 p.
 article
28 Comparison of long-term humoral memory development after immunisation against Neisseria meningitidis B or diphtheria toxoid Cruz, Simone C.
 2010
 28 Supplement 3 p. 6841-6846
6 p.
 article
29 Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen Hospers, Geke A.P.
 2009
 28 Supplement 3 p. 386-391
6 p.
 article
30 Control of EHV-1 viremia and nasal shedding by commercial vaccines Goehring, L.S.
 2010
 28 Supplement 3 p. 5203-5211
9 p.
 article
31 Corrigendum to “The member of the cyclic di-nucleotide family bis-(3′,5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant” [Vaccine 28 (2010) 2249–2258] Libanova, Rimma
 2010
 28 Supplement 3 p. 3625-
1 p.
 article
32 CpG oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by a goose parvovirus vaccine in ducks Lee, Jai-Wei
 2010
 28 Supplement 3 p. 7956-7962
7 p.
 article
33 Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant Sui, Zhiwei
 2010
 28 Supplement 3 p. 7690-7698
9 p.
 article
34 Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years Weinberger, Birgit
 2010
 28 Supplement 3 p. 3511-3515
5 p.
 article
35 Development and characterization of a modified Komarov's bullet for ballistic delivery of live Brucella abortus strains 82 and 19 to cattle and bison Denisov, Alexander A.
 2010
 28 Supplement 3 p. F23-F30
nvt p.
 article
36 Development and immunogenicity of a recombinant pseudorabies virus expressing Sj26GST and SjFABP from Schistosoma japonicum Wei, Feng
 2010
 28 Supplement 3 p. 5161-5166
6 p.
 article
37 Development of a simple and high-yielding fed-batch process for the production of influenza vaccines Meghrous, Jamal
 2009
 28 Supplement 3 p. 309-316
8 p.
 article
38 Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis Bhattacharya, Debaditya
 2010
 28 Supplement 3 p. 7683-7689
7 p.
 article
39 Development of novel lipidated analogs of picroside as vaccine adjuvants: Acylated analogs of picroside-II elicit strong Th1 and Th2 response to ovalbumin in mice Kumar, H.M. Sampath
 2010
 28 Supplement 3 p. 8327-8337
11 p.
 article
40 Differential activation of host cell signalling pathways through infection with two variants of influenza A/Puerto Rico/8/34 (H1N1) in MDCK cells Heynisch, B.
 2010
 28 Supplement 3 p. 8210-8218
9 p.
 article
41 DNA-mediated vaccination conferring protection against infectious bursal disease in broiler chickens in the presence of maternal antibody Hsieh, Ming Kun
 2010
 28 Supplement 3 p. 3936-3943
8 p.
 article
42 DNA vaccine against human papillomavirus type 16: Modifications of the E6 oncogene Poláková, Ingrid
 2010
 28 Supplement 3 p. 1506-1513
8 p.
 article
43 Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever Froeschle, James E.
 2010
 28 Supplement 3 p. 1451-1453
3 p.
 article
44 Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan de Blasio, Birgitte Freiesleben
 2010
 28 Supplement 3 p. 7923-7932
10 p.
 article
45 Editorial Board 2010
 28 Supplement 3 p. CO2-
1 p.
 article
46 Editorial Board 2010
 28 Supplement 3 p. CO2-
1 p.
 article
47 Editorial Board 2010
 28 Supplement 3 p. CO2-
1 p.
 article
48 Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA Desai, Sachin N.
 2010
 28 Supplement 3 p. 7501-7506
6 p.
 article
49 Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group B Flitter, Becca A.
 2010
 28 Supplement 3 p. 5967-5972
6 p.
 article
50 Effect of influenza-like illness and other wintertime respiratory illnesses on worker productivity: The child and household influenza-illness and employee function (CHIEF) study Palmer, Liisa A.
 2010
 28 Supplement 3 p. 5049-5056
8 p.
 article
51 Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices Bourinbaiar, Aldar S.
 2010
 28 Supplement 3 p. 2763-2768
6 p.
 article
52 Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant Hepatitis B vaccination Soh, Shu E
 2010
 28 Supplement 3 p. 2577-2579
3 p.
 article
53 Effects of astragalus polysaccharides on immunologic function of erythrocyte in chickens infected with infectious bursa disease virus Jiang, Junbing
 2010
 28 Supplement 3 p. 5614-5616
3 p.
 article
54 Engineering filamentous phage carriers to improve focusing of antibody responses against peptides van Houten, Nienke E.
 2010
 28 Supplement 3 p. 2174-2185
 article
55 Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens Li, Lijin
 2010
 28 Supplement 3 p. 1911-1918
8 p.
 article
56 Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis Nagill, Rajeev
 2010
 28 Supplement 3 p. 4002-4012
11 p.
 article
57 Evaluation of hepatic changes and local and systemic immune responses in goats immunized with recombinant Peroxiredoxin (Prx) and challenged with Fasciola hepatica Mendes, Ricardo E.
 2010
 28 Supplement 3 p. 2832-2840
9 p.
 article
58 Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep Dungu, Baptiste
 2010
 28 Supplement 3 p. 4581-4587
7 p.
 article
59 Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits Heldens, J.G.M.
 2010
 28 Supplement 3 p. 8125-8131
7 p.
 article
60 Flow cytometric assessment of chicken T cell-mediated immune responses after Newcastle disease virus vaccination and challenge Dalgaard, T.S.
 2010
 28 Supplement 3 p. 4506-4514
9 p.
 article
61 Folding domains within the ricin toxin A subunit as targets of protective antibodies O’Hara, Joanne M.
 2010
 28 Supplement 3 p. 7035-7046
12 p.
 article
62 Frequent failure of adolescent booster responses to tetanus toxoid despite infant immunization: Waning of infancy-induced immune memory? Posfay-Barbe, Klara M.
 2010
 28 Supplement 3 p. 4356-4361
6 p.
 article
63 Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets Partridge, Jeffrey
 2010
 28 Supplement 3 p. 4709-4712
4 p.
 article
64 GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis Lu, Ying-Jie
 2010
 28 Supplement 3 p. 7468-7475
8 p.
 article
65 Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice Noland, Gregory S.
 2010
 28 Supplement 3 p. 2917-2923
7 p.
 article
66 High costs of influenza: Direct medical costs of influenza disease in young children Fairbrother, Gerry
 2010
 28 Supplement 3 p. 4913-4919
7 p.
 article
67 Humoral immune responses in brushtail possums (Trichosurus vulpecula) induced by bacterial ghosts expressing possum zona pellucida 3 protein Cui, Xianlan
 2010
 28 Supplement 3 p. 4268-4274
7 p.
 article
68 Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues Kopp, Nadja
 2009
 28 Supplement 3 p. 261-269
9 p.
 article
69 Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans Tan, Tze Guan
 2010
 28 Supplement 3 p. 3977-3989
13 p.
 article
70 Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly Kao, Tsui Mai
 2010
 28 Supplement 3 p. 6159-6163
5 p.
 article
71 Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220 Overton, E.T.
 2010
 28 Supplement 3 p. 5597-5604
8 p.
 article
72 Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: Results from the EBMT IDWP01 trial Cordonnier, Catherine
 2010
 28 Supplement 3 p. 2730-2734
5 p.
 article
73 Immunization and challenge experiments with a new modified live bovine herpesvirus type 1 marker vaccine prototype adjuvanted with a co-polymer Kalthoff, Donata
 2010
 28 Supplement 3 p. 5871-5877
7 p.
 article
74 Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates Dupuy, Lesley C.
 2010
 28 Supplement 3 p. 7345-7350
6 p.
 article
75 Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents Lu, Chun-Yi
 2010
 28 Supplement 3 p. 5864-5870
7 p.
 article
76 Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years Tregnaghi, Miguel W.
 2010
 28 Supplement 3 p. 3595-3601
7 p.
 article
77 Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age Kaltenböck, A.
 2010
 28 Supplement 3 p. 834-839
6 p.
 article
78 Immunogenicity and safety of the human rotavirus vaccine Rotarix™ co-administered with routine infant vaccines following the vaccination schedules in Europe Vesikari, Timo
 2010
 28 Supplement 3 p. 5272-5279
8 p.
 article
79 Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves Xue, Wenzhi
 2010
 28 Supplement 3 p. 3784-3792
9 p.
 article
80 Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: Using PRNT50 as an endpoint for immunogenicity Reisler, Ronald B.
 2010
 28 Supplement 3 p. 2436-2441
6 p.
 article
81 Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials Torresi, Joseph
 2010
 28 Supplement 3 p. 7993-8000
8 p.
 article
82 Immunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis Borja-Cabrera, G.P.
 2010
 28 Supplement 3 p. 597-603
7 p.
 article
83 Impact of influenza vaccination of schoolchildren on medical outcomes among all residents of Maryland King Jr., James C.
 2010
 28 Supplement 3 p. 7737-7742
6 p.
 article
84 Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains Lee, Vernon J.
 2010
 28 Supplement 3 p. 6852-6857
6 p.
 article
85 Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule Vestrheim, Didrik F.
 2010
 28 Supplement 3 p. 2214-2221
 article
86 Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes Brave, Andreas
 2010
 28 Supplement 3 p. 2080-2087
8 p.
 article
87 Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant Xu, Gui-lian
 2010
 28 Supplement 3 p. 7221-7227
7 p.
 article
88 Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara®) Roukens, Anna H.
 2010
 28 Supplement 3 p. 4288-4293
6 p.
 article
89 Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge Barefoot, Brice E.
 2009
 28 Supplement 3 p. 79-89
11 p.
 article
90 Intranasal immunization with Leish-111f induces IFN-γ production and protects mice from Leishmania major infection Sakai, Shun-ichi
 2010
 28 Supplement 3 p. 2207-2213
 article
91 Intranasal immunization with vaccine vector Streptococcus gordonii elicits primed CD4+ and CD8+ T cells in the genital and intestinal tracts Ciabattini, Annalisa
 2010
 28 Supplement 3 p. 1226-1233
8 p.
 article
92 In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6 von Teichman, Beate F.
 2010
 28 Supplement 3 p. 6505-6517
13 p.
 article
93 Isolation and analysis of the vaccine potential of an attenuated Edwardsiella tarda strain Sun, Yun
 2010
 28 Supplement 3 p. 6344-6350
7 p.
 article
94 J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells Taylor, P.R.
 2010
 28 Supplement 3 p. 5533-5542
10 p.
 article
95 Knowledge and acceptability of the HPV vaccine by school children and their parents in Birmingham Das, A.
 2010
 28 Supplement 3 p. 1440-1446
7 p.
 article
96 Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response Wang, Danan
 2010
 28 Supplement 3 p. 3134-3142
9 p.
 article
97 Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51 Dubischar-Kastner, Katrin
 2010
 28 Supplement 3 p. 5197-5202
6 p.
 article
98 MALVAC 2009: Progress and Challenges in Development of Whole Organism Malaria Vaccines for Endemic Countries, 3–4 June 2009, Dakar, Senegal Pinder, M.
 2010
 28 Supplement 3 p. 4695-4702
8 p.
 article
99 MCV vaccination in the presence of vaccine-associated Guillain–Barré Syndrome risk: A decision analysis approach Cho, Bo-Hyun
 2010
 28 Supplement 3 p. 817-822
6 p.
 article
100 Modulation of inter-vaccination interval to avoid antigenic competition in multivalent footrot (Dichelobacter nodosus) vaccines in sheep Dhungyel, Om P.
 2009
 28 Supplement 3 p. 470-473
4 p.
 article
101 Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004 Brockhoff, Heinrich J.
 2010
 28 Supplement 3 p. 2932-2936
5 p.
 article
102 Mumps vaccine associated orchitis: Evidence supporting a potential immune-mediated mechanism Clifford, Vanessa
 2010
 28 Supplement 3 p. 2671-2673
3 p.
 article
103 Murine neutralizing antibody response and toxicity to synthetic peptides derived from E1 and E2 proteins of hepatitis C virus El-Awady, Mostafa K.
 2010
 28 Supplement 3 p. 8338-8344
7 p.
 article
104 Mycobacterial cell-wall skeleton as a universal vaccine vehicle for antigen conjugation Paik, Tae-Hyun
 2010
 28 Supplement 3 p. 7873-7880
8 p.
 article
105 National Immunization Technical Advisory Groups (NITAGs): Guidance for their establishment and strengthening Duclos, Philippe
 2010
 28 Supplement 3 p. A18-A25
nvt p.
 article
106 Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows Imoto, Jun-ichi
 2010
 28 Supplement 3 p. 7373-7380
8 p.
 article
107 Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice Yuan, Lin
 2010
 28 Supplement 3 p. 4402-4410
9 p.
 article
108 Parental attitude towards childhood HBV vaccination in The Netherlands Hontelez, Jan A.C.
 2010
 28 Supplement 3 p. 1015-1020
6 p.
 article
109 Passive protection effect of chicken egg yolk immunoglobulins on enterovirus 71 infected mice Liou, Jenn-Fa
 2010
 28 Supplement 3 p. 8189-8196
8 p.
 article
110 Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines Chuck, Anderson W.
 2010
 28 Supplement 3 p. 5485-5490
6 p.
 article
111 Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults Pierce, Mark A.
 2010
 28 Supplement 3 p. 2236-2242
 article
112 Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen O’Neill, Ciaragh
 2010
 28 Supplement 3 p. 4871-4874
4 p.
 article
113 Porcine lactoferrin administration enhances peripheral lymphocyte proliferation and assists infectious bursal disease vaccination in native chickens Hung, Che-Ming
 2010
 28 Supplement 3 p. 2895-2902
8 p.
 article
114 Positive attitudes of French general practitioners towards A/H1N1 influenza-pandemic vaccination: A missed opportunity to increase vaccination uptakes in the general public? Schwarzinger, Michaël
 2010
 28 Supplement 3 p. 2743-2748
6 p.
 article
115 Potential epidemiological and economical impact of two rotavirus vaccines in Colombia De la Hoz, Fernando
 2010
 28 Supplement 3 p. 3856-3864
9 p.
 article
116 Prevalence of high-risk indications for influenza vaccine varies by age, race, and income Zimmerman, Richard K.
 2010
 28 Supplement 3 p. 6470-6477
8 p.
 article
117 Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity Machado, Alexandre V.
 2010
 28 Supplement 3 p. 3247-3256
10 p.
 article
118 Protection of BALB/c mice against Brucella melitensis 16M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein Al-Mariri, Ayman
 2010
 28 Supplement 3 p. 1766-1770
5 p.
 article
119 Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein Zhou, Xuemei
 2010
 28 Supplement 3 p. 3990-3996
7 p.
 article
120 Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines Wysocki, J.
 2010
 28 Supplement 3 p. 7779-7786
8 p.
 article
121 Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection Cummings, James F.
 2010
 28 Supplement 3 p. 5135-5144
10 p.
 article
122 Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice Ranganathan, Uma Devi K.
 2009
 28 Supplement 3 p. 152-161
10 p.
 article
123 Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17–18 February 2010 Girard, Marc P.
 2010
 28 Supplement 3 p. 6811-6820
10 p.
 article
124 Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization Li, Guifan
 2010
 28 Supplement 3 p. 4215-4223
9 p.
 article
125 Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: A phase I–II randomized trial Wu, Jiang
 2010
 28 Supplement 3 p. 6221-6227
7 p.
 article
126 Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: A prospective, open-label, multi-center trial Oh, Chi-Eun
 2010
 28 Supplement 3 p. 5857-5863
7 p.
 article
127 Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults Treanor, John J.
 2010
 28 Supplement 3 p. 8268-8274
7 p.
 article
128 Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers Tribble, D.
 2010
 28 Supplement 3 p. 6076-6085
10 p.
 article
129 Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults Frey, Sharon E.
 2010
 28 Supplement 3 p. 6367-6373
7 p.
 article
130 Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon Mordmüller, Benjamin
 2010
 28 Supplement 3 p. 6698-6703
6 p.
 article
131 Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy Russell, F.M.
 2010
 28 Supplement 3 p. 3086-3094
9 p.
 article
132 Safety profile of live varicella virus vaccine (Oka/Merck): Five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP) Goulleret, Nicolas
 2010
 28 Supplement 3 p. 5878-5882
5 p.
 article
133 Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing Le Ru, Audrey
 2010
 28 Supplement 3 p. 3661-3671
11 p.
 article
134 Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination Shuaibu, M.N.
 2010
 28 Supplement 3 p. 6868-6875
8 p.
 article
135 Seroconversion following incomplete human rabies postexposure prophylaxis Robertson, Kis
 2010
 28 Supplement 3 p. 6523-6526
4 p.
 article
136 Serologic testing to verify the immune status of internationally adopted children against vaccine preventable diseases Staat, Mary Allen
 2010
 28 Supplement 3 p. 7947-7955
9 p.
 article
137 Serotype distribution of invasive pneumococcal disease during the first 60 days of life Imöhl, Matthias
 2010
 28 Supplement 3 p. 4758-4762
5 p.
 article
138 Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI) Leav, Brett A.
 2010
 28 Supplement 3 p. 965-969
5 p.
 article
139 Severe combined immunodeficiency (SCID) and rotavirus vaccination: Reports to the Vaccine Adverse Events Reporting System (VAERS) Bakare, Nyasha
 2010
 28 Supplement 3 p. 6609-6612
4 p.
 article
140 Smallpox vaccine with integrated IL-15 demonstrates enhanced in vivo viral clearance in immunodeficient mice and confers long term protection against a lethal monkeypox challenge in cynomolgus monkeys Zielinski, Rafal J.
 2010
 28 Supplement 3 p. 7081-7091
11 p.
 article
141 Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant Xue, Xiangyang
 2010
 28 Supplement 3 p. 3152-3158
7 p.
 article
142 Stable seroepidemiology of hepatitis B after universal immunization in Taiwan: A 3-year study of national surveillance of primary school students Chen, Ching-Yi
 2010
 28 Supplement 3 p. 5605-5608
4 p.
 article
143 Structure–activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2 Zaman, Mehfuz
 2010
 28 Supplement 3 p. 2243-2248
 article
144 Study on the efficacy of Leptospira vaccines developed from serovars isolated from Trinidad and comparison with commercial vaccines using a hamster model Suepaul, S.M.
 2010
 28 Supplement 3 p. 5421-5426
6 p.
 article
145 Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10 Kraigher, Alenka
 2010
 28 Supplement 3 p. 5467-5472
6 p.
 article
146 Systematic review of interventions to increase influenza vaccination rates of those 60 years and older Thomas, Roger E.
 2010
 28 Supplement 3 p. 1684-1701
18 p.
 article
147 The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages Fabrizio, Kevin
 2010
 28 Supplement 3 p. 7542-7550
9 p.
 article
148 The epidemiology of chickenpox in UK 5-year olds: An analysis to inform vaccine policy Manikkavasagan, Gayatri
 2010
 28 Supplement 3 p. 7699-7705
7 p.
 article
149 The Eurocine® L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination Petersson, Pernilla
 2010
 28 Supplement 3 p. 6491-6497
7 p.
 article
150 The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox Heinsbroek, Ellen
 2010
 28 Supplement 3 p. 3778-3783
6 p.
 article
151 The member of the cyclic di-nucleotide family bis-(3′, 5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant Libanova, Rimma
 2010
 28 Supplement 3 p. 2249-2258
 article
152 The National Committee for Vaccines Regulation and Surveillance of Vaccine-Preventable Diseases in the Sultanate of Oman: Evidence-based approach and consensus decision-making Al Awaidy, Salah
 2010
 28 Supplement 3 p. A39-A41
nvt p.
 article
153 The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant Chen, Wangxue
 2010
 28 Supplement 3 p. 3080-3085
6 p.
 article
154 The RTS,S malaria vaccine Casares, Sofia
 2010
 28 Supplement 3 p. 4880-4894
15 p.
 article
155 The seroepidemiology of Bordetella pertussis in Israel—Estimate of incidence of infection Rendi-Wagner, Pamela
 2010
 28 Supplement 3 p. 3285-3290
6 p.
 article
156 Tracking parental attitudes on vaccination across European countries: The Vaccine Safety, Attitudes, Training and Communication Project (VACSATC) Stefanoff, Pawel
 2010
 28 Supplement 3 p. 5731-5737
7 p.
 article
157 Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE Trigo, Joelma
 2010
 28 Supplement 3 p. 3333-3340
8 p.
 article
158 Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: Meeting at the Crossroads Madore, Dace V.
 2010
 28 Supplement 3 p. 4539-4547
9 p.
 article
159 Vaccination of commercial broiler chicks against avian metapneumovirus infection: a comparison of drinking-water, spray and oculo-oral delivery methods Ganapathy, Kannan
 2010
 28 Supplement 3 p. 3944-3948
5 p.
 article
160 Vaccination strategies for managing brucellosis in Yellowstone bison Treanor, John J.
 2010
 28 Supplement 3 p. F64-F72
nvt p.
 article
161 Vaccination with peptide mimotopes produces antibodies recognizing bacterial capsular polysaccharides Wu, Yang
 2010
 28 Supplement 3 p. 6425-6435
11 p.
 article
162 Vaccine efficacy of porcine reproductive and respiratory syndrome virus chimeras Ellingson, Joshua S.
 2010
 28 Supplement 3 p. 2679-2686
8 p.
 article
163 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: Effectiveness of a 2-dose versus 3-dose primary series Pelton, Stephen I.
 2010
 28 Supplement 3 p. 1575-1582
8 p.
 article
                             163 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands